On Friday, October 13th, the Food and Drug Administration (FDA) Advisory Panel unanimously recommended approval of Spark Therapeutics gene therapy for Leber Congenital Amaurosis (LCA). Click here to read more. Final approval, if it happens, would take place in early 2018. If so, it will be the first FDA approved gene therapy for an eye disorder and, as of right now, only the second FDA approved gene therapy in the United States. Here are a few key points you should know:
As many of you know, Dr. Nowakowski and Dr. DeCarlo discussed this very drug in their lecture titled, "Gene Therapy - The Ultimate Low Vision Aid?" in August at our Summer Conference. In a similar, quite timely fashion, Spark Therapeutics was also in attendance as one of VisionAmerica's vendors. We hope you are planning to attend next year's Vision Summer Conference for more cutting edge, and maybe even prescient, presentations.
0 Comments
Leave a Reply. |
AuthorThe staff and doctors at VisionAmerica are committed to providing relevant information for you, your patients and your practice. We hope you find the information in our blog post helpful. Archives
August 2019
Categories |